Země: Malta
Jazyk: angličtina
Zdroj: Medicines Authority
REPAGLINIDE
Sigillata Limited (Ireland) Inniscarra, Main Street, Rathcoole, Co. Dublin D24 E029 , Ireland
A10BX02
REPAGLINIDE 0.5 mg
TABLET
REPAGLINIDE 0.5 mg
POM
DRUGS USED IN DIABETES
Authorised
2010-07-14
Page 1 of 6 PACKAGE LEAFLET Page 2 of 6 PACKAGE LEAFLET: INFORMATION FOR THE USER ILGAPER 0.5 MG TABLETS ILGAPER 1 MG TABLETS ILGAPER 2 MG TABLETS ILGAPER 4 MG TABLETS Repaglinide READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET: 1. WHAT ILGAPER IS AND WHAT IT IS USED FOR 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE ILGAPER 3. HOW TO TAKE ILGAPER 4. POSSIBLE SIDE EFFECTS 5. HOW TO STORE ILGAPER 6. CONTENTS OF THE PACK AND OTHER INFORMATION 1. WHAT ILGAPER IS AND WHAT IT IS USED FOR Ilgaper is an _oral antidiabetic medicine containing repaglinide _ which helps your pancreas produce more insulin and thereby lower your blood sugar (glucose). TYPE 2 DIABETES is a disease in which your pancreas does not make enough insulin to control the sugar in your blood or where your body does not respond normally to the insulin it produces. Ilgaper is used to control type 2 diabetes in adults as an add-on to diet and exercise: treatment is usually started if diet, exercise and weight reduction alone have not been able to control (or lower) your blood sugar. Ilgaper can also be given with metformin, another medicine for diabetes. Ilgaper has been shown to lower the blood sugar, which helps to prevent complications from your diabetes. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE ILGAPER DO NOT TAKE ILGAPER: - if you are ALLERGIC to repaglinide or any of the other ingredients in this medicine (listed in section 6). - if you have TYPE 1 DIABETES . - if the acid level in your blood is raised ( DIABETIC KETOACIDOSIS ). - if you have a Přečtěte si celý dokument
Page 1 of 11 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Ilgaper 0.5 mg tablets Ilgaper 1 mg tablets Ilgaper 2 mg tablets Ilgaper 4 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 0.5 mg, 1 mg, 2 mg or 4 mg of repaglinide. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Tablet Ilgaper 0.5 mg tablets are white, round, biconvex and engraved with RE on one side. Ilgaper 1 mg tablets are mottled yellow, round, biconvex and engraved with RE1 on one side. Ilgaper 2 mg tablets are mottled pink, round, biconvex and engraved with RE2 on one side. Ilgaper 4 mg tablets are mottled pink, round, biconvex and engraved with RE4 on one side. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Repaglinide is indicated in adults with type 2 diabetes mellitus whose hyperglycaemia can no longer be controlled satisfactorily by diet, weight reduction and exercise. Repaglinide is also indicated in combination with metformin in adults with type 2 diabetes mellitus who are not satisfactorily controlled on metformin alone. Treatment should be initiated as an adjunct to diet and exercise to lower the blood glucose in relation to meals. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology Repaglinide is given preprandially and is titrated individually to optimise glycaemic control. In addition to the usual self-monitoring by the patient of blood and/or urinary glucose, the patient’s blood glucose must be monitored periodically by the physician to determine the minimum effective dose for the patient. Glycosylated haemoglobin levels are also of value in monitoring the patient’s response to therapy. Periodic monitoring is necessary to detect inadequate lowering of blood glucose at the recommended maximum dose level (i.e. primary failure) and to detect loss of adequate blood glucose lowering response after an initial period of effectiveness (i.e. secondary failure). Short-term administration of repaglinide may be sufficient during periods of transient loss of control Přečtěte si celý dokument